The diagnostic usefulness of the combined COMPASS 31 questionnaire and electrochemical skin conductance for diabetic cardiovascular autonomic neuropathy and diabetic polyneuropathy

Cinzia D'Amato, Carla Greco, Giorgio Lombardo, Valentina Frattina, Mariagrazia Campo, Chiara M A Cefalo, Valentina Izzo, Davide Lauro, Vincenza Spallone, Cinzia D'Amato, Carla Greco, Giorgio Lombardo, Valentina Frattina, Mariagrazia Campo, Chiara M A Cefalo, Valentina Izzo, Davide Lauro, Vincenza Spallone

Abstract

The study investigated the diagnostic performance for diabetic cardiovascular autonomic neuropathy (CAN) and diabetic polyneuropathy (DPN) of the combined use of composite autonomic symptom score (COMPASS) 31, validated questionnaire for autonomic symptoms of CAN, and electrochemical skin conductance (ESC), proposed for detecting DPN and CAN. One-hundred and two participants with diabetes (age 57 ± 14 years, duration 17 ± 13 years) completed the COMPASS 31 before assessing cardiovascular reflex tests (CARTs), neuropathic symptoms, signs, vibratory perception threshold (VPT), thermal thresholds (TT), and ESC using Sudoscan. Two patterns were evaluated: (a) the combined abnormalities in both tests (COMPASS 31+ESC), and (b) the abnormality in COMPASS 31 and/or ESC (COMPASS 31 and/or ESC). CAN (≥1 abnormal CART) and confirmed CAN (≥2 abnormal CARTs) were present in 28.1% and 12.5%, DPN (two abnormalities among symptoms, signs, VPT, and TT) in 52%, abnormal COMPASS 31 (total weighted score >16.44) in 48% and abnormal ESC (hands ESC <50 μS and/or feet ESC <70 μS) in 47.4%. Both the patterns-COMPASS 31+ESC and COMPASS 31 and/or ESC-were associated with CAN and DPN (P < .01). COMPASS 31 and ESC reached a sensitivity of 75% and 83% for confirmed CAN, and a specificity of 65% and 67% for DPN. When combining the tests, the sensitivity for CAN rose by up to 100% for CAN and the specificity up to 89% for DPN. The combination of the tests can allow a stepwise screening strategy for CAN, by suggesting CAN absence with combined normality, and prompting to CARTs with combined abnormality.

Keywords: diabetes; diagnosis; neuropathy; sudomotor function; symptoms.

© 2020 Peripheral Nerve Society.

References

REFERENCES

    1. England JD, Gronseth GS, Franklin G, et al. American Academy of Neurology. Practice parameter: evaluation of distal symmetric polyneuropathy: role of autonomic testing, nerve biopsy, and skin biopsy (an evidence-based review). Report of the American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine, and American Academy of Physical Medicine and Rehabilitation. Neurology. 2009;72:177-184.
    1. Spallone V, Ziegler D, Freeman R, et al. Toronto consensus panel on diabetic neuropathy. Cardiovascular autonomic neuropathy in diabetes: clinical impact, assessment, diagnosis, and management. Diabetes Metab Res Rev. 2011;27:639-653.
    1. Pop-Busui R, Boulton AJ, Feldman EL, et al. Diabetic neuropathy: a position statement by the American Diabetes Association. Diabetes Care. 2017;40:136-154.
    1. Suarez GA, Opfer-Gehrking TL, Offord KP, Atkinson EJ, O'Brien PC, Low PA. The autonomic symptom profile: a new instrument to assess autonomic symptoms. Neurology. 1999;52:523-528.
    1. Low PA, Benrud-Larson LM, Sletten DM, et al. Autonomic symptoms and diabetic neuropathy: a population-based study. Diabetes Care. 2004;27:2942-2947.
    1. Sletten DM, Suarez GA, Low PA, Mandrekar J, Singer W. COMPASS 31: a refined and abbreviated composite autonomic symptom score. Mayo Clin Proc. 2012;87:1196-1201.
    1. Pierangeli G, Turrini A, Giannini G, et al. Translation and linguistic validation of the composite autonomic symptom score COMPASS 31. Neurol Sci. 2015;36:1897-1902.
    1. Greco C, Di Gennaro F, D'Amato C, et al. Validation of the composite autonomic symptom score 31 (COMPASS 31) for the assessment of symptoms of autonomic neuropathy in people with diabetes. Diabet Med. 2017;34:834-838.
    1. Assessment: clinical autonomic testing report of the therapeutics and technology assessment Subcommittee of the American Academy of neurology. Neurology. 1996;46:873-880.
    1. Kempler P, Amarenco G, Freeman R, et al. Toronto consensus panel on diabetic neuropathy. Management strategies for gastrointestinal, erectile, bladder, and sudomotor dysfunction in patients with diabetes. Diabetes Metab Res Rev. 2011;27:665-677.
    1. Buchmann SJ, Penzlin AI, Kubasch ML, Illigens BM, Siepmann T. Assessment of sudomotor function. Clin Auton Res. 2019;29:41-53.
    1. Calvet JH, Dupin J, Winiecki H, Schwarz PE. Assessment of small fiber neuropathy through a quick, simple and non invasive method in a German diabetes outpatient clinic. Exp Clin Endocrinol Diabetes. 2013;121:80-83.
    1. Casellini CM, Parson HK, Richardson MS, Nevoret ML, Vinik AI. Sudoscan, a noninvasive tool for detecting diabetic small fiber neuropathy and autonomic dysfunction. Diabetes Technol Ther. 2013;15:948-953.
    1. Selvarajah D, Cash T, Davies J, et al. SUDOSCAN: a simple, rapid, and objective method with potential for screening for diabetic peripheral neuropathy. PLoS One. 2015;10:e0138224.
    1. Novak P. Electrochemical skin conductance: a systematic review. Clin Auton Res. 2019;29:17-29.
    1. Rajan S, Campagnolo M, Callaghan B, Gibbons CH. Sudomotor function testing by electrochemical skin conductance: does it really measure sudomotor function? Clin Auton Res. 2019;29:31-39.
    1. Yajnik CS, Kantikar VV, Pande AJ, Deslypere JP. Quick and simple evaluation of sudomotor function for screening of diabetic neuropathy. ISRN Endocrinol. 2012;2012:103714.
    1. Eranki VG, Santosh R, Rajitha K, et al. Sudomotor function assessment as a screening tool for microvascular complications in type 2 diabetes. Diabetes Res Clin Pract. 2013;101:e11-e13.
    1. Smith AG, Lessard M, Reyna S, Doudova M, Singleton JR. The diagnostic utility of Sudoscan for distal symmetric peripheral neuropathy. J Diabetes Complications. 2014;28:511-516.
    1. Sheshah E, Madanat A, Al-Greesheh F, et al. Electrochemical skin conductance to detect sudomotor dysfunction, peripheral neuropathy and the risk of foot ulceration among Saudi patients with diabetes mellitus. J Diabetes Metab Disord. 2016;15:29.
    1. Goel A, Shivaprasad C, Kolly A, Sarathi HAV, Atluri S. Comparison of electrochemical skin conductance and vibration perception threshold measurement in the detection of early diabetic neuropathy. PLoS One. 2017;12:e0183973.
    1. Krieger SM, Reimann M, Haase R, Henkel E, Hanefeld M, Ziemssen T. Sudomotor testing of diabetes polyneuropathy. Front Neurol. 2018;9:803.
    1. Carbajal-Ramírez A, Hernández-Domínguez JA, Molina-Ayala MA, Rojas-Uribe MM, Chávez-Negrete A. Early identification of peripheral neuropathy based on sudomotor dysfunction in Mexican patients with type 2 diabetes. BMC Neurol. 2019;19:109.
    1. Cabré JJ, Mur T, Costa B, et al. Catalan diabetes prevention research group. Feasibility and effectiveness of electrochemical dermal conductance measurement for the screening of diabetic neuropathy in primary care. Decoding study (dermal electrochemical conductance in diabetic neuropathy). J Clin Med. 2019;8:598.
    1. Yajnik CS, Kantikar V, Pande A, et al. Screening of cardiovascular autonomic neuropathy in patients with diabetes using non-invasive quick and simple assessment of sudomotor function. Diabetes Metab. 2013;39:126-131.
    1. Yuan T, Li J, Fu Y, et al. A cardiac risk score based on sudomotor function to evaluate cardiovascular autonomic neuropathy in asymptomatic Chinese patients with diabetes mellitus. PLoS One. 2018;13:e0204804.
    1. Shivaprasad C, Amit G, Anish K, Rakesh B, Anupam B, Aiswarya Y. Clinical correlates of sudomotor dysfunction in patients with type 2 diabetes and peripheral neuropathy. Diabetes Res Clin Pract. 2018;139:188-194.
    1. Greco C, D'Amato C, Di Gennaro F, et al. Diagnostic value of different autonomic symptoms assessed by COMPASS 31 for cardiovascular autonomic neuropathy and diabetic polyneuropathy. Diabetologia. 2017;60(suppl 1):S989-S989.
    1. Spallone V, Bellavere F, Scionti L, et al. Recommendations for the use of cardiovascular tests in diagnosing diabetic autonomic neuropathy. Nutr Metab Cardiovasc Dis. 2011;21:69-78.
    1. Tesfaye S, Boulton AJ, Dyck PJ, et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care. 2010;33:2285-2293.
    1. Feldman EL, Stevens MJ, Thomas PK, Brown MB, Canal N, Greene DA. A practical two-step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy. Diabetes Care. 1994;17:1281-1289.
    1. Bril V, Perkins BA. Comparison of vibration perception thresholds obtained with the Neurothesiometer and the CASE IV and relationship to nerve conduction studies. Diabet Med. 2002;19:661-666.
    1. Bax G, Fagherazzi C, Piarulli F, Nicolucci A, Fedele D. Reproducibility of Michigan Neuropathy Screening Instrument (MNSI). A comparison with tests using the vibratory and thermal perception thresholds. Diabetes Care. 1996;19:904-905.
    1. Zinman LH, Bril V, Perkins BA. Cooling detection thresholds in the assessment of diabetic sensory polyneuropathy: comparison of CASE IV and Medoc instruments. Diabetes Care. 2004;27:1674-1679.
    1. Mayaudon H, Miloche PO, Bauduceau B. A new simple method for assessing sudomotor function: relevance in type 2 diabetes. Diabetes Metab. 2010;36:450-454.
    1. Ziemssen T, Siepmann T. The investigation of the cardiovascular and Sudomotor autonomic nervous system-a review. Front Neurol. 2019;10:53.
    1. Vinik AI, Smith AG, Singleton JR, et al. Normative values for electrochemical skin conductances and impact of ethnicity on quantitative assessment of Sudomotor function. Diabetes Technol Ther. 2016;18:391-398.
    1. Petrie A, Sabin C. Medical Statistics at a Glance. 1st ed. Oxford: Blackwell Science; 2000.
    1. Zilliox L, Peltier AC, Wren PA, et al. Assessing autonomic dysfunction in early diabetic neuropathy: the survey of autonomic symptoms. Neurology. 2011;22(76):1099-1105.
    1. Binns-Hall O, Selvarajah D, Sanger D, Walker J, Scott A, Tesfaye S. One-stop microvascular screening service: an effective model for the early detection of diabetic peripheral neuropathy and the high-risk foot. Diabet Med. 2018;35:887-894.
    1. Mao F, Liu S, Qiao X, et al. Sudoscan is an effective screening method for asymptomatic diabetic neuropathy in Chinese type 2 diabetes mellitus patients. J Diabetes Investig. 2017;8:363-368.
    1. Conceição I, de Castro I, Castro J. Correlation between Sudoscan and COMPASS 31: assessment of autonomic dysfunction on hATTR V30M patients. Amyloid. 2019;26(suppl 1):23.
    1. Duchesne M, Richard L, Vallat JM, Magy L. Assessing sudomotor impairment in patients with peripheral neuropathy: comparison between electrochemical skin conductance and skin biopsy. Clin Neurophysiol. 2018;129:1341-1348.
    1. Yan A, Issar T, Tummanapalli SS, et al. Relationship between corneal confocal microscopy and markers of peripheral nerve structure and function in Type 2 diabetes. Diabet Med. 2020;37:326-334.
    1. Casellini CM, Parson HK, Hodges K, et al. Bariatric surgery restores cardiac and Sudomotor autonomic C-fiber dysfunction towards Normal in obese subjects with type 2 diabetes. PLoS One. 2016;11:e0154211.
    1. Ang L, Jaiswal M, Callaghan B, Raffel D, B Brown M, Popbusui R. Sudomotor dysfunction as a measure of small fiber neuropathy in type 1 diabetes. Auton Neurosci. 2017;205:87-92.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren